ABSTRACT
AIM: our aim was to see the efficiency of Bonviva(Ibadronates) among in osteoporoses among women. OBJECTIVES: We chose this medicament which has the most acceptable price by all the GDP women's family and also this medicament which is at the new line of biphosphonate (Ibadronates), and has the most commodity of taken ones per monthly. For our proposal we include in our study all women age 45 -60 years old (average 52.6 +/- 41), which have a physiologic menopause. All case was selected from ambulatory service without other diseases such are neoplasic which affect the bone, renal (creatinine clirens < 40 ml/min), gastrointestinal, respiratory and high blood pressure were or have allergy from Bonviva excluded or from our study. The final number of subjects was 89 women. The women at the moment of selection have or no osteoporotic fracture. We measure also the high, age, weight, BMI but except age other were not analyzed form us. The measure of body mass density (BMD) is the gold standard for to establish the diagnosis of osteoporosis. All subjects we measure the index of T-score (which represent the BMD), at the lumbar part of spine, which show the efficiency of Bonviva. T-Score was measure before treatment, after six months and after one year. The T-score was measure by DE XA (lunate one). RESULTS: In order to measure the efficiency of Bonvines all cases the T-Score were analyzed from SPSS version 15 with ANOVA. The results of ANOVA show statistical significance (p < 0.0001) between BMD before treatment (-3.12 +/- 0.49), BMD six months after treatment (-2.9 +/- 0.5) and after BMD one year (-2.7 +/- 0.5). The significance was also high (P < 0.0001) when we compare also BMD six month and after one year. CONCLUSIONS: Our results show the efficiency of Bonviva among women with pre, during and post menopause in osteoporoses. Ibadronate (Bonviva) increase the BMD in women with early menopauses, as results we prevent osteoporosis. Bonviva increases the BMD in women with established osteoporoses, as results we reduce the vertebral risk fracture.
